Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite TreatmentBy / 19/09/2023 Caliway Biopharmaceuticals announced the completion of subject recruitment in the CBL-0201EFP Phase 2-stage 2 study.
